Your new post is loading...
Research and publish the best content.
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Already have an account: Login
Bioscience News - GEG Tech top picks
8.8K views |
+0 today
To investigate the roles and therapeutic potential for targeting the RORs in type 1 diabetes, the scientists administered SR1001, a selective RORα/γ inverse agonist, to non-obese diabetic (NOD) mice. SR1001 significantly reduced diabetes incidence and insulitis in treated mice. Furthermore, SR1001 reduced pro-inflammatory cytokine expression, particularly TH17-mediated cytokines, reduced autoantibody production, and increased the frequency of CD4+Foxp3+ T regulatory cells.
www.geg-tech.com